Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205675
Type of treatment:
Allogeneic - Unrelated
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
Primary objective:
The objective of the study is to evaluate the outcome of patients with MDS who underwent allogeneic HSCT and received GvHD prophylaxis with cyclophosphamide post-transplantation compared to those who received Antithymocyte Globulin (ATG).
The primary endpoint of the study is GvHD-free/relapse free survival (GRFS).
The primary endpoint of the study is GvHD-free/relapse free survival (GRFS).
Key inclusion criteria:
o Diagnosis of MDS or MDS transformed to AML before first allogeneic HSCT.
o Adults (≥18 years) at time of transplantation.
o First allogeneic HSCT between 2012-2019.
o Stem cell source: bone marrow or peripheral blood from an unrelated donor.
o Post-cyclophosphamide (post-CY) as GvHD prophylaxis or Antithymocyte Globulin (ATG) as conditioning or GvHD prophylaxis treatment.
o Adults (≥18 years) at time of transplantation.
o First allogeneic HSCT between 2012-2019.
o Stem cell source: bone marrow or peripheral blood from an unrelated donor.
o Post-cyclophosphamide (post-CY) as GvHD prophylaxis or Antithymocyte Globulin (ATG) as conditioning or GvHD prophylaxis treatment.
Country:
All EBMT member countries
Principal investigator:
Yves Chalandon, Marie Robin
EBMT Study coordinator:
Laurien Baaij
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results